Abstracts tagged "COVID-19"

Abstract Number: 2044 • ACR Convergence 2024
Clinical Practice Patterns, Rilonacept Appropriate Use for Recurrent Pericarditis
Jessica Farrell¹, Michael Allen², Lee Shapiro³, Victoria Michaels⁴, Arifa Javed⁵, Nabiha Qureshi⁶, Summia Matin Afridi⁷, Shahad Almahmoud⁸, Getzabeth Bosques Gomez⁹ and Khoa Richard Ngo¹⁰, ¹Albany College of Pharmacy & Health Sciences/Albany Medical Center, Delmar, NY, ²Albany Medical Center, Delmar, NY, ³Albany Medical College, Stillwater, NY, ⁴Albany Medical Center, Wynantskill, NY, ⁵Albany Medical Center, Rensselaer, NY, ⁶Albany Medical Center, Menands, NY, ⁷Albany Medical Center, Albany, NY, ⁸Albany College of Pharmacy & Health Sciences/Albany Medical Center, Albany, NY, ⁹Albany College of Pharmacy and Health Sciences/Albany Medical Center, Albany, NY, ¹⁰Albany Medical Center, Voorheesville, NY
Background/Purpose: Pericarditis is inflammation of the pericardial sac which can be of infectious or non-infectious etiology, commonly associated with rheumatic diseases. Pericarditis is defined as…
Abstract Number: 0238 • ACR Convergence 2024
Longitudinal Assessment of CD8+ T Cell Responses to SARS-CoV-2 Pre- and Post-breakthrough Infection and Its Association with COVID-19 Severity in Immunosuppressed Individuals
Aljawharah Alrubayyi¹, Aaron Shulkin¹, Judith James², Meggan Mackay³, Dinesh Khanna⁴, Amit Bar-Or⁵, Susan Macwana⁶, Ellen Goldmuntz⁷, James McNamara⁸, Sean McCarthy⁹, Matthew Sherman⁸, William Barry¹⁰, Ashley Pinckney¹¹, Sarah Walker¹⁰, Sara Tedeschi¹², Jeffrey Sparks¹³, Zachary Wallace¹⁴ and Gaurav Gaiha¹⁵, ¹Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Feinstein Institutes for Medical Research, Manhasset, NY, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Oklahoma Medical Research Foundation, Oklahoma City, ⁷NIAID/ NIH, Washington, DC, ⁸NIH, Bethesda, MD, ⁹DAIT/NIAID/NIH, Rockville, MD, ¹⁰Rho, Durham, NC, ¹¹Rho, St Louis Park, NC, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ¹⁴Massachusetts General Hospital, Newton, MA, ¹⁵Massachusetts General Hospital, Boston, MA
Background/Purpose: Vaccines for SARS-CoV-2 have greatly reduced COVID-19 morbidity and mortality through the induction of neutralizing antibody responses. However, T cell responses are also induced…
Abstract Number: 1110 • ACR Convergence 2024
Microvascular Abnormalities in COVID-19 Survivors and LONG COVID
Rosanna Campitiello¹, Emanuele Gotelli², Elvis Hysa³, Carmen Pizzorni⁴, Alberto Sulli⁵, Sabrina Paolino⁶, Alessandro Pinelli⁷, Tamara Vojinovic², vanessa smith⁸ and Maurizio Cutolo², ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Liguria, Italy, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ³Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁵Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Genova, Italy, ⁶Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Specialties (Di.M.I.), University of Genova; IRCCS Ospedale Policlinico San Martino, Genova, Liguria, Italy, ⁷Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Specialties (Di.M.I.), University of Genova; IRCCS Ospedale Policlinico San Martino, Genova, ⁸Ghent University Hospital, Gent, Belgium
Background/Purpose: Coronavirus disease 2019 (COVID-19) is an infective disease known to cause mainly respiratory symptoms along with a wide range of systemic manifestations [1]. Long…
Abstract Number: 2056 • ACR Convergence 2024
Deucravacitinib Treatment Did Not Impact Immune Response to SARS-CoV-2 Vaccines and Infection in Patients with Plaque Psoriasis: Results from the Phase 3 POETYK Long-Term Extension Trial
Kevin Winthrop¹, Joseph Merola², Akimichi Morita³, Diamant Thaçi⁴, Jianzhong Zhang⁵, Aditi Basu Ba⁶, Ian M. Catlett⁷, John Schwarz⁶ and Yi Luo⁶, ¹School of Medicine, Oregon Health and Science University, Portland, OR, ²UT Southwestern Medical Center, Newton, MA, ³Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁴Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, ⁵Department of Dermatology, Peking University People’s Hospital, Beijing, China, ⁶Bristol Myers Squibb, Princeton, ⁷Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…
Abstract Number: 0239 • ACR Convergence 2024
Neutralising Antibody Responses to Bivalent SARS-CoV-2 Vaccines and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
Hilde S. Ørbo¹, Taissa M. Kasahara², Asia-Sophia Wolf³, Kristin H. Bjørlykke⁴, Joseph Sexton⁵, Ingrid Jyssum⁵, Anne Therese Tveter⁵, Guri Solum³, Ingrid Fadum Kjønstad³, Andreas Lind⁶, Veselka Petrova Dimova-Svetoslavova⁶, Tore K. Kvien⁷, Jørgen Jahnsen⁸, Espen A. Haavardsholm¹, Ludvig A. Munthe⁹, Sella A. Provan⁵, John Torgils Vaage⁹, Siri Mjaaland³, Kristin K. Jørgensen⁴, Gunnveig Grødeland⁹, Silje W. Syversen¹⁰ and Guro L. Goll¹⁰, ¹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ²University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ³Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, ⁴Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Oslo University Hospital, Department of Microbiology, Oslo, Norway, Oslo, Norway, ⁷Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁸Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, ⁹Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway
Background/Purpose: The SARS-CoV-2 virus mutates continuously, posing challenges for patients with immune-mediated inflammatory diseases (IMIDs) on tumour necrosis factor inhibitors (TNFi). These patients often have…
Abstract Number: 1146 • ACR Convergence 2024
Impact of COVID-19 on Myositis Testing Trends
Angel Kevin Garza-Elizondo¹, Rosa Icela Arvizu-Rivera², Pablo Gamez-Siller³, Daniela Alejandra Salcedo-Soto⁴, Jesus Cardenas-de la Garza⁵, Gisela Garcia-Arellano⁶, Miguel Angel Villarreal-Alarcon² and Dionicio Galarza-Delgado⁷, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁶Hospital Universitario \"Dr. José Eleuterio González\", Monterrey, Nuevo León, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM), also known as myositis, are a group of heterogeneous autoimmune disorders that lead to muscle injury. Autoantibodies help make the…
Abstract Number: 2091 • ACR Convergence 2024
Changes in Analgesic Prescriptions for the Treatment of Osteoarthritis During the COVID-19 Pandemic
Derek Ochi¹, Dagoberto Pina², Manmeet Kaur³, Jeffery Fine⁴, Daniel Black⁵ and Barton Wise⁶, ¹Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis, Sacramento, CA, ²School of Medicine, University of California Davis, Sacramento, CA, ³Division of Rheumatology, Allergy and Immunology, University of California San Diego, San Diego, CA, ⁴Department of Public Health Sciences, University of California Davis, Sacramento, CA, ⁵Innovation Technology - Data Center of Excellence, University of California Davis, Sacramento, CA, ⁶Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis and Department of Orthopaedic Surgery, University of California Davis, Sacramneto, CA
Background/Purpose: Osteoarthritis (OA) is a leading cause of disability. The 2019 American College of Rheumatology (ACR)/Arthritis Foundation (AF) Guideline for the Management of OA recommends…
Abstract Number: 0240 • ACR Convergence 2024
Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
Hilde S. Ørbo¹, Asia-Sophia Wolf², Taissa M. Kasahara³, Kristin H. Bjørlykke⁴, Ingrid Jyssum⁵, Joseph Sexton⁵, Anne Therese Tveter⁵, Guri Solum², Ingrid Fadum Kjønstad², Ingrid E. Christensen⁵, Tore K. Kvien⁶, Jørgen Jahnsen⁷, Espen A. Haavardsholm¹, Ludvig A. Munthe⁸, Sella A. Provan⁵, John Torgils Vaage⁸, Kristin K. Jørgensen⁴, Gunnveig Grødeland⁸, Siri Mjaaland², Silje W. Syversen⁹ and Guro L. Goll⁹, ¹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ²Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, ³University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁷Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, ⁸Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated humoral vaccine responses and are prone to more severe infections. Assessing the persistence…
Abstract Number: 1201 • ACR Convergence 2024
Association of COVID-19 Vaccinations with Osteoarthritis Flares: A Case-Crossover Study
Minerva Nong¹, Colby Lewis V², Genna Braverman³, Vivian Bykerk³, Nathaniel Hupert², Medha Barbhaiya³ and Lisa Mandl³, ¹Hospital for Special Surgery, Tampa, FL, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: People with osteoarthritis (OA) commonly experience periods of increased pain and stiffness (“flares”), which can be distressing and disabling. Despite the prevalence of OA…
Abstract Number: 2182 • ACR Convergence 2024
PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results
Gina Montealegre Sanchez¹, Lauren Arrigoni², Kevin Rubenstein³, Max Wolff⁴, Mallory Barrix², C. Jason Liang⁵, James Bost⁶, Meghan Delaney⁷, Luigi Notarangelo⁸, Karyl Barron⁹ and Roberta DeBiasi¹⁰, and PECOS Study Team, ¹Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID),National Institutes of Health (NIH), Bethesda, MD, ²Center for Cancer and Immunology Research (CCIR), Children's National Research Institute, Washington, DC, ³Clinical Monitoring Research Program Directorate (CMRPD), National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, MD, ⁴Clinical Research Directorate (CRD), National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, MD, ⁵Biostatistics Research Branch, NIAID, NIH, Bethesda, MD, ⁶Division of Biostatistics and Study Methodology and Center for Translational Research, Children's National Research Institute, Washington, DC, ⁷Department of Pathology and Laboratory Medicine, Children's National Hospital, Washington, DC, ⁸Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, Bethesda, MD, ⁹Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, ¹⁰Children's National Hospital and Research Institute, Washington, DC
Background/Purpose: The long-term sequelae of SARS-CoV-2 infection in children are unknown. PECOS is a large prospective observational cohort study with the main objective to characterize…
Abstract Number: 0241 • ACR Convergence 2024
Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients
Rebecca Sadun¹, Dan Crair¹, Emmanuel Walter¹, Eugene St.Clair², David Pisetsky², Amanda Eudy³, Megan Clowse⁴, Jennifer Rogers⁵, Kai Sun¹, Lisa Criscione-Schreiber⁶, Mithu Maheswaranathan⁶, Jayanth Doss¹, Sarah Valencia¹ and M. Athony Moody⁷, ¹Duke University, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Duke University, Raleigh, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke, Durham, NC, ⁶Duke University School of Medicine, Durham, NC, ⁷Duke University School of Medicine, Durham
Background/Purpose: The ACR recommends SARS-CoV-2 vaccination for all patients with rheumatic diseases, but it is unknown how patients with SLE will respond to the vaccine,…
Abstract Number: 1249 • ACR Convergence 2024
Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Shilpa Venkatachalam¹, Kelly Gavigan², Erik Stone³, Angela Degrassi², Laura Stradford⁴, David Curtis², Esteban Rivera⁵ and Jeffrey Curtis⁶, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, Upper Nyack, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…
Abstract Number: 2198 • ACR Convergence 2024
Severe and Long-Term Outcomes of COVID-19 Infection and Vaccine Hesitancy and Adverse Events in Children with Pediatric Rheumatic Diseases: Insights from a COVID-19 Global Rheumatology Alliance Caregiver Survey
Jonathan Hausmann¹, Kevin Kennedy², Ethan Knapp³, Nadine Lalonde⁴, jOhn Wallace⁵, Richard Howard⁶, Marcela Alvarez⁷, Mariana Fabi⁸, Lorena Franco⁹, Rebecca Grainger¹⁰, Jean Liew¹¹, Pedro M Machado¹², Zachary Wallace¹³, Jinoos Yazdany¹⁴ and Emily Sirotich¹⁵, and COVID-19 Global Rheumatology Alliance, ¹Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ²McMaster University, Hamilton, ON, Canada, ³University of Connecticut School of Medicine, Farmington, CT, ⁴COVID-19 Global Rheumatology Alliance, London, ON, Canada, ⁵Covid 19 Global Rheumatology Alliance Patient Board, EDINBURGH, United Kingdom, ⁶Spondylitis Association of America, Encino, CA, ⁷CHIDRENS HOSPITAL DR. RICARDO GUTIERREZ ARGENTINA, Buenos Aires, Argentina, ⁸Argentine Society of Rheumatology, La Plata, Argentina, ⁹Argentine Society of Rheumatology, Cordoba, Argentina, ¹⁰University of Otago, Wellington, New Zealand, ¹¹Boston University, Boston, MA, ¹²Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ¹³Massachusetts General Hospital, Newton, MA, ¹⁴UCSF, San Francisco, CA, ¹⁵Yale University, Vaughan, ON, Canada
Background/Purpose: Children have the lowest COVID-19 vaccination rates of any age group. In adults with rheumatic diseases, barriers to vaccination include the perceived lack of…
Abstract Number: 0152 • ACR Convergence 2023
Long Covid in Persons with Self-Reported Arthritis – Symptoms, Associated Factors and Functional Limitations
Debbie Ehrmann Feldman¹ and Barbara Mazer², ¹Université de Montréal, Montreal, QC, Canada, ²McGill University, Montreal, QC, Canada
Background/Purpose: Long covid, a condition whereby signs and symptoms post covid-19 infection continue for more than 12 weeks and are not explained by an alternative…
Abstract Number: 0223 • ACR Convergence 2023
Severity and Risk Factors of Hospitalization of Omicron in Patients with Rheumatoid Arthritis
Yan Wang¹, mengyao zhang², Sitian Zang¹, liang luo³, Chun Li¹, Jing He¹ and zhanguo li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University People's Hospital, Beijing, China, ³Department of Chinese Medicine, the People's Hospital of Yubei District of Chongqing City, Chongqing, China; Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: There is still lack of data on the prognosis of patients with RA who have been infected with SARS-Cov-2 Omicron variant, a new strain…

« Previous Page
1
…
3
4
5
6
7
…
40
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].